182 related articles for article (PubMed ID: 33393006)
21. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
22. TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling.
Ke X; Zhao Y; Lu X; Wang Z; Liu Y; Ren M; Lu G; Zhang D; Sun Z; Xu Z; Song JH; Cheng Y; Meltzer SJ; He S
Oncotarget; 2015 Oct; 6(32):32610-21. PubMed ID: 26416455
[TBL] [Abstract][Full Text] [Related]
23. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways.
Cheng J; Zhong Y; Chen S; Sun Y; Huang L; Kang Y; Chen B; Chen G; Wang F; Tian Y; Liu W; Feng GS; Lu Z
FASEB J; 2017 Dec; 31(12):5530-5542. PubMed ID: 28842424
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway.
Zhang N; Chu ES; Zhang J; Li X; Liang Q; Chen J; Chen M; Teoh N; Farrell G; Sung JJ; Yu J
Oncotarget; 2014 Sep; 5(18):8330-40. PubMed ID: 25327562
[TBL] [Abstract][Full Text] [Related]
25. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
26. DJ-1 promotes development of DEN-induced hepatocellular carcinoma and proliferation of liver cancer cells.
Qiu B; Wang J; Yu Y; Zhen C; Gu J; Liu W; Wen Y; Chen L; Gao Y; Xia Q; Kong X
Oncotarget; 2017 Jan; 8(5):8499-8511. PubMed ID: 28036277
[TBL] [Abstract][Full Text] [Related]
27. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Shi Y; Fu Y; Zhang X; Zhao G; Yao Y; Guo Y; Ma G; Bai S; Li H
Cancer Immunol Immunother; 2021 Jan; 70(1):61-73. PubMed ID: 32632663
[TBL] [Abstract][Full Text] [Related]
28. Two distinct Notch signals, Delta-like 4/Notch1 and Jagged-1/Notch2, antagonistically regulate chemical hepatocarcinogenesis in mice.
Nakano Y; Nakao S; Sueoka M; Kasahara D; Tanno Y; Sumiyoshi H; Itoh T; Miyajima A; Hozumi K; Inagaki Y
Commun Biol; 2022 Jan; 5(1):85. PubMed ID: 35064244
[TBL] [Abstract][Full Text] [Related]
29. Activation of SRY accounts for male-specific hepatocarcinogenesis: Implication in gender disparity of hepatocellular carcinoma.
Liu C; Ren YF; Dong J; Ke MY; Ma F; Monga SPS; Wu R; Lv Y; Zhang XF
Cancer Lett; 2017 Dec; 410():20-31. PubMed ID: 28942012
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
32. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
33. STAT3 and AKT signaling pathways mediate oncogenic role of NRSF in hepatocellular carcinoma.
Ma M; Zhou Y; Sun R; Shi J; Tan Y; Yang H; Zhang M; Shen R; Xu L; Wang Z; Fei J
Acta Biochim Biophys Sin (Shanghai); 2020 Oct; 52(10):1063-1070. PubMed ID: 32556117
[TBL] [Abstract][Full Text] [Related]
34. Time serial transcriptome reveals
Wang Q; Tang Q; Zhao L; Zhang Q; Wu Y; Hu H; Liu L; Liu X; Zhu Y; Guo A; Yang X
Cancer Biol Med; 2020 May; 17(2):401-417. PubMed ID: 32587777
[No Abstract] [Full Text] [Related]
35. BMP activated Smad signaling strongly promotes migration and invasion of hepatocellular carcinoma cells.
Maegdefrau U; Bosserhoff AK
Exp Mol Pathol; 2012 Feb; 92(1):74-81. PubMed ID: 22024355
[TBL] [Abstract][Full Text] [Related]
36. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
[TBL] [Abstract][Full Text] [Related]
37. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells.
Zhang S; Yang Y; Liang Z; Duan W; Yang J; Yan J; Wang N; Feng W; Ding M; Nie Y; Jin Z
PLoS One; 2013; 8(12):e83699. PubMed ID: 24386256
[TBL] [Abstract][Full Text] [Related]
38. Promotive effects of bone morphogenetic protein 2 on angiogenesis in hepatocarcinoma via multiple signal pathways.
Zuo WH; Zeng P; Chen X; Lu YJ; Li A; Wu JB
Sci Rep; 2016 Nov; 6():37499. PubMed ID: 27886213
[TBL] [Abstract][Full Text] [Related]
39. Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells.
Wu WR; Zhang R; Shi XD; Yi C; Xu LB; Liu C
Oncol Rep; 2016 Jul; 36(1):181-8. PubMed ID: 27221981
[TBL] [Abstract][Full Text] [Related]
40. Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2.
Khan H; Jia W; Yu Z; Zaib T; Feng J; Jiang Y; Song H; Bai Y; Yang B; Feng H
Biomed Pharmacother; 2020 Aug; 128():110244. PubMed ID: 32464306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
